Volume 18 Issue 1, March 2024

Breaking barriers with JCR Pharmaceuticals

In Conversation
- Breaking barriers to deliver brain biotherapeutics
  
  In conversation with Hiroyuki Sonoda, VP, Research & Corporate Strategy Executive Director, Research Division, JCR Pharmaceuticals
  
  Advertisement Feature 26 Jan 2024
  
  Advertisement

Top of page ⤴

Genome-editing technologies take off

Feature
- A CRISPR collaboration compilation
  
  Major biopharma companies are partnering with pioneers of genome-editing technologies to realize the potential of this emerging precision medicine modality.
  
  Biopharma Dealmakers
  
  Collection:
  
  What’s next for molecular diagnostics and precision medicine?
  News Feature 19 Feb 2024
Profiles
- Long-lasting genetic therapeutics for debilitating neurological conditions
  
  Cognigenics is using advanced gene-editing techniques to develop intranasal treatments that target neural networks associated with anxiety and memory disorders, which could yield long-term solutions.
  
  Cognigenics
  
  Collection:
  
  What’s next for molecular diagnostics and precision medicine?
  Advertisement Feature 01 Feb 2024
- Cutting insights
  
  CRISPR QC’s chip platform-enabling efficiency that aims to power the next generation of CRISPR therapies.
  
  CRISPR QC
  
  Collection:
  
  What’s next for molecular diagnostics and precision medicine?
  Advertisement Feature 16 Feb 2024
- Harnessing antifibrotic drugs to prevent breast cancer metastasis
  
  Venture-backed start-up MeCo Diagnostics has developed a first-in-class, clinically validated, prognostic and predictive biomarker test to enable targeted antifibrotic therapy for early-stage breast cancer patients.
  
  MeCo Diagnostics
  
  Collection:
  
  What’s next for molecular diagnostics and precision medicine?
  Advertisement Feature 01 Feb 2024
- Precision CRISPR for in vivo genome engineering
  
  Combining first-in-class delivery and engineering tools, Ensoma is developing one-time in vivo treatments that can precisely engineer any cell of the blood and immune systems to cure diseases from within.
  
  Ensoma, Inc.
  
  Collection:
  
  What’s next for molecular diagnostics and precision medicine?
  Advertisement Feature 01 Feb 2024
- A novel blood test to advance cancer care for solid tumors
  
  Screening and diagnostics based on the detection of cancer-generated cellular biomarkers.
  
  Creatv MicroTech, Inc.
  
  Collection:
  
  What’s next for molecular diagnostics and precision medicine?
  Advertisement Feature 01 Feb 2024

Top of page ⤴

A new era for radiopharmaceuticals

Feature
- The radiopharmaceutical renaissance: radiating hope in cancer therapy
  
  The commercial success of second-generation radiopharmaceuticals in oncology has re-ignited interest in this modality, resulting in a surge of dealmaking and increased venture financing for companies in the field.
  
  Brianne Sullivan
  Andrew Davis
  Peter Bak
  
  Collection:
  
  Advances in oncology drug development
  News Feature 01 Mar 2024
Profiles
- AlgenBrain: reverse-engineering disease trajectories with CRISPR and AI
  
  Algen Biotechnologies’ unique functional genomics technologies tease apart complex disease biology using human-centric therapeutic endpoints to identify novel targets and best-in-class molecules.
  
  Algen Biotechnologies
  
  Collection:
  
  Advances in oncology drug development
  Advertisement Feature 01 Mar 2024
- Prioritizing partnerships to get ahead of disease
  
  By coupling its expertise, scale, and technologies with those of like-minded biopharma partners GSK is striving to make a real difference for patients.
  
  GSK Business Development
  
  Collection:
  
  Advances in oncology drug development
  Advertisement Feature 01 Mar 2024
- Developing a new cancer immunotherapy, SurVaxM from bench to bedside
  
  MimiVax, Inc. is developing immunotherapeutic vaccines and targeted therapies for treating cancers and preventing recurrence. The company’s lead agent, SurVaxM, targets survivin, a cell-survival protein expressed in cancer cells.
  
  MimiVax, Inc.
  
  Collection:
  
  Advances in oncology drug development
  Advertisement Feature 01 Mar 2024
- KDDF bolsters the development of innovative cancer therapies
  
  The government-funded Korea Drug Development Fund (KDDF) is investing in companies developing next-generation anticancer drugs.
  
  Korea Drug Development Fund (KDDF)
  
  Collection:
  
  Advances in oncology drug development
  Advertisement Feature 01 Mar 2024
- ResponderID: the future of RNA biomarkers is now
  
  Genialis is the RNA biomarker company; it espouses a people-first approach to machine learning–driven biomarker discovery. For targeted therapies to benefit the most patients possible, Genialis develops predictive biomarkers to guide treatment decisions. The company’s next-generation biomarkers work for real patients by informing targeted treatment decisions for better outcomes.
  
  Genialis, Inc.
  
  Collection:
  
  Advances in oncology drug development
  Advertisement Feature 01 Mar 2024

Top of page ⤴

Volume 18 Issue 1, March 2024

In this issue...

Breaking barriers with JCR Pharmaceuticals

In Conversation

Breaking barriers to deliver brain biotherapeutics

Genome-editing technologies take off

Feature

A CRISPR collaboration compilation

Profiles

Long-lasting genetic therapeutics for debilitating neurological conditions

Cutting insights

Harnessing antifibrotic drugs to prevent breast cancer metastasis

Precision CRISPR for in vivo genome engineering

A novel blood test to advance cancer care for solid tumors

A new era for radiopharmaceuticals

Feature

The radiopharmaceutical renaissance: radiating hope in cancer therapy

Profiles

AlgenBrain: reverse-engineering disease trajectories with CRISPR and AI

Prioritizing partnerships to get ahead of disease

Developing a new cancer immunotherapy, SurVaxM from bench to bedside

KDDF bolsters the development of innovative cancer therapies

ResponderID: the future of RNA biomarkers is now

Search

Quick links